Envista (NVST) to Release Quarterly Earnings on Wednesday

Envista (NYSE:NVST) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Envista to post earnings of $0.33 per share and revenue of $716.4940 million for the quarter. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $705.50 million during the quarter, compared to analysts’ expectations of $680.03 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The firm’s revenue for the quarter was up 14.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 earnings per share. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Envista Price Performance

Shares of NYSE:NVST opened at $27.00 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The company has a market cap of $4.39 billion, a P/E ratio of 65.85, a PEG ratio of 1.51 and a beta of 0.86. Envista has a 52 week low of $18.77 and a 52 week high of $30.42. The company has a 50-day moving average price of $25.34 and a 200 day moving average price of $25.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its holdings in Envista by 1,442.7% in the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after buying an additional 2,263,712 shares in the last quarter. Holocene Advisors LP purchased a new stake in shares of Envista during the 2nd quarter worth approximately $43,936,000. Alliancebernstein L.P. boosted its stake in shares of Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after acquiring an additional 1,547,656 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in shares of Envista in the 4th quarter worth approximately $29,046,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Envista in the 3rd quarter worth approximately $24,260,000.

Analyst Ratings Changes

Several equities analysts have issued reports on NVST shares. Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings cut Envista from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 11th. BMO Capital Markets initiated coverage on Envista in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price target on the stock. Citigroup assumed coverage on Envista in a report on Wednesday, April 15th. They set a “neutral” rating and a $29.00 price objective on the stock. Finally, Evercore reiterated an “outperform” rating and issued a $33.00 price objective on shares of Envista in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.54.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.